Zamtocabtagene Autoleucel (Zamto-Cel), a Tandem CD20-CD19 Directed CAR-T cell Therapy As Second-Line Treatment for relapsed/refractory Large B-cell Lymphoma: Primary analysis of the Randomized, Pivotal DALY 2-EU Study
作者
Peter Borchmann,Tom van Meerten,Pierre Bories,Peter Dreger,László Gopcsa,Pim G. N. J. Mutsaers,Matthias Edinger,Lajos Gergely,Bastian von Tresckow,Peter Neumeister,Normann Steiner,Ulrich Jäger,Ana Triguero Moreno,Laimonas Griškevičius,Gloria Iacoboni,François Lemonnier,Jaap A. van Doesum,Nirav Niranjan Shah,Rimas J. Orentas,Birte Friedrichs